In a most recent study, nine TNBC patients, who were originally excluded for atezolizumab treatment based on criteria of the IMpassion130 trial, were treated with atezolizumab and the IHC of their tumor tissues were subjected to the deglycosylation process by glycosydase in order to better measure PD‐L1 level on the tumor cells.12 Here, CD274 is linked to neoplasm.